Choline protects against cardiac hypertrophy induced by increased after-load

International Journal of Biological Sciences

Volumn 9, Issue 3, 2013, Pages 295-302

  Zhao, Yilei ^a   Wang, Chen ^a   Wu, Jianwei ^a   Wang, Yan ^a   Zhu, Wenliang ^a   Zhang, Yong ^a   Du, Zhimin ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Calcineurin; Cardiac hypertrophy; Cardiomyocyte; Choline; miR 133a

Indexed keywords

CALCINEURIN; CARDIOTONIC AGENT; CHOLINE; ISOPRENALINE; MICRORNA; MIRN133 MICRORNA, MOUSE;

ANIMAL; ARTICLE; CALCINEURIN.; CARDIOMEGALY; CARDIOMYOCYTE; CELL CULTURE; CHEMICALLY INDUCED DISORDER; DOWN REGULATION; DRUG EFFECT; GENETIC MARKER; HEART MUSCLE; HEART VENTRICLE HYPERTROPHY; MALE; METABOLISM; MIR-133A; MOUSE; MOUSE STRAIN; ORGAN SIZE; PATHOLOGY; RAT; SIGNAL TRANSDUCTION;

CALCINEURIN.; CARDIAC HYPERTROPHY; CARDIOMYOCYTE; CHOLINE; MIR-133A;

ANIMALS; CALCINEURIN; CARDIOMEGALY; CARDIOTONIC AGENTS; CELLS, CULTURED; CHOLINE; DOWN-REGULATION; GENETIC MARKERS; ISOPROTERENOL; MALE; MICE; MICE, INBRED STRAINS; MICRORNAS; MYOCARDIUM; ORGAN SIZE; RATS; SIGNAL TRANSDUCTION;

EID: 84875098971     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.5976     Document Type: Article

References (29)

1. Zeisel SH, da Costa KA. Choline: an essential nutrient for public health. Nutr Rev. 2009; 67: 615-623.
2. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA. 2002; 288: 2015-2022.
3. Glunde K, Bhujwalla ZM, Ronen SM. Choline metabolism in malignant transformation. Nat Rev Cancer. 2011; 11: 835-848.
4. Pan Z, Guo Y, Qi H, Fan K, Wang S, Zhao H, Fan Y, Xie J, Guo F, Hou Y, Wang N., Huo R, Zhang Y, Liu Y, Du Z. M3 Subtype of Muscarinic Acetylcholine Receptor Promotes Cardio-protection via the Suppression of miR-376b-5p. PLoS One. 2012; 7:e32571.
5. Yang BF, Lin HX, Xu CQ, Liu Y, Wang H, Han H, Wang Z. Choline produces cytoprotective effects against ischemic myocardial injuries: Evidence for the role of cardiac M3 subtype muscarinic acetylcholine receptors. Cell Physiol Biochem. 2005; 16: 163-174.
6. Liu Y, Sun HL, Li DL, Wang LY, Gao Y, Wang YP, Du ZM, Lu YJ, Yang BF. Choline produces antiarrhythmic actions in animal models by cardiac M3 receptors: improvement of Intracellular Ca2+ handlingas a commonmechanism. Can J Physiol Pharmacol. 2008; 86: 860-865.
7. Wang S, Han HM, Pan ZW, Hang PZ, Sun LH, Jiang YN, Song HX, Du ZM, Liu Y. Choline inhibits angiotensin II-induced cardiac hypertrophy by intracellular calcium signal and p38 MAPK pathway. Naunyn-Schmiedeberg's Arch Pharmacol. 2012; 385: 823-831.
8. Balakumara P, Jagadeeshb G. Multifarious molecular signaling cascades of cardiac hypertrophy: Can the muddy waters be cleared? Pharmacological Research. 2010; 62: 365-383.
9. Bernardo BC, Weeks KL, Pretorius L, McMullen JR. Molecular distinction between physiological and pathological cardiac hypertrophy: Experimental findings and therapeutic strategies. Pharmacology & Therapeutics. 2010; 128: 191-227.
10. Carè A, Catalucci D, Felicetti F, Bonci D, Addario A, Gallo P, Bang ML, et al. MicroRNA-133 controls cardiac hypertrophy. Nature medicine. 2007; 13: 613-618.
11. Dong DL, Chen C, Huo R, Wang N, Li Z, Tu Y, Chu X, Huang W, Yang BF. T Reciprocal repression between microRNA-133 and calcineurin regulates cardiac hypertrophy: a novel mechanism for progressive cardiac hypertrophy. Hypertension. 2010; 55: 946-952.
12. Hang PZ, Zhao JL, Wang YP, Sun LH, Zhang Y, Yang LL, Zhao N, Sun ZD, Mao Y, Du ZM. Reciprocal regulation between M3 muscarinic acetylcholine receptor and protein kinase C-ε in ventricular myocytes during myocardial ischemia in rats. Naunyn-Schmied Arch Pharmacol. 2009; 380: 443-450.
13. Wang YP, Hang PZ, Sun LH, Zhang Y, Zhao JL, Pan ZW, Ji H., Wang L, Bi H, Du ZM. M3 muscarinic acetylcholine receptor is associated with β-catenin in myocytes duringmyocardial infraction in the rat. Clinical and Experimental Pharmacology and Physiology. 2009; 36: 995-1001.
14. Zhao J, Su Y, Zhang Y, Pan Z, Yang L, Chen XC, Liu Y, Lu YJ, Du ZM, Yang BF. Activation of cardiac muscarinic M3 receptors induces delayed cardioprotection by preserving phosphorylated connexin43 and upreg ulating cyclooxygenase-2 expression. Br J Pharmacol. 2010; 159: 1217-1225.
15. Liao Y, Ishikura F, Beppu S, Asakura M, Takashima S, Asanuma H, Sanada S, Kim J, Ogita H, Kuzuya T, Node K, Kitakaze M, Hori M. Echocardiographic assessment of LV hypertrophy an function in aortic-banded mice: necropsy validation. Am Physiol Heart Circ Physiol. 2002; 282: H1703-H1708.
16. Kuhn M, Szklarczyk D, Franceschini A, Csmpillos M, Von M, Jensen LJ, Beyer A, Bork P. STITCH 2: an interaction network database for small molecules and proteins. Nucleic Acids Res. 2010; 38(Database issue): D552-D556.
17. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003;13: 2498-2504.
18. Bauer-Mehren A, Rautschka M, Sanz F, Furlonget L. DisGeNET: a Cytoscape plugin to visualize, integrate, search and analyze gene-disease networks. Bioinformatics. 2010; 26: 2924-2926.
19. Martin A, Ochagavia ME, Rabasa LC, Miranda J, Fernandez-de-Cossio J. BisoGenet: a new tool for gene network building, visualization and analysis. BMC Bioinformatics 2010; 11: 91.
20. Berry JM, Naseem RH, Rothermel BA, Hill J. Models of cardiac hypertrophy and transition to heart failure. Drug Discovery Today: Disease Models. 2007; 4: 198-206.
21. Sesca E, Chiara M, Binasco V, Tessitore L. The delay in rat liver regeneration by choline is associated to alteration in c-myc expression. Boll Soc Ital Biol Sper. 1996; 72: 217-222.
22. Johansson J, Formaggio E, Fumagalli G, Chiamulera C. Choline up-regulates BDNF and down-regulates TrkB neurotrophin receptor in rat cortical cell culture. Neuroreport. 2009; 20: 828-832.
23. Cazzolli R, Huang P, Teng S, Hughes WE. Measuring phospholipase D activity in insulin-secreting pancreatic beta-cells and insulin-responsive muscle cells and adipocytes. Methods Mol Biol. 2009; 462: 241-251.
24. Napoli I, Blusztajn JK, Mellott TJ. Prenatal choline supplementation in rats increases the expression of IGF2 and its receptor IGF2R and enhances IGF2-induced acetylcholine release in hippocampus and frontal cortex. Brain Res. 2008; 1237: 124-135.
25. Li Q, Lin X, Yang X, Chang J. NFATc4 is negatively regulated in miR-133a-mediated cardiomyocyte hypertrophic repression. Am J Physiol Heart Circ Physiol. 2010; 298: H1340-1347.
26. Tan XY, Li JP, Wang XY, Chen N, Cai BZ, Wang G, Shan HL, Dong DL, Liu YJ, Li XD, Yang F, Li X, Zhang P, Li XQ, Yang BF, Lu YJ. Tanshinone IIA Protects Against Cardiac Hypertrophy via Inhibiting Calcineurin/ Nfatc3 Pathway. Int J Biol Sci. 2011; 7: 383-389.
27. Chen C, Huo R, Tong Y, Sheng Y, Liu HB, Gao X, Nakajima O, Yang BF, Dong DL. Systemic Heme Oxygenase-1 Transgenic Overexpression Aggravates Pressure Overload-induced Cardiac Hypertrophy in Mice. Cell Physiol Biochem. 2011; 28: 25-32.
28. Donaldson C, Eder S, Baker C, Aronovitz MJ, Weiss AD, Hall-Porter M, Wang F, Ackerman A, Karas RH, Molkentin JD, Patten RD. Estrogen attenuates left ventricular and cardiomyocyte hypertrophy by an estrogen receptor-dependent pathway that increases calcineurin degradation. Circ Res. 2009; 104: 265-275.
29. Villar AV, Merino D, Wenner M, Liano M, Cobo M. Myocardial gene expression of microRNA-133a and myosin heavy and light chains, in conjunction with clinical parameters, predict regression of left ventricular hypertrophy after valve replacement in patients with aortic stenosis. Heart. 2011; 97: 1132-1137.